Nine-valent HPV vaccine - new generation of HPV vaccine

被引：0
|
作者：
Fait, T. [1 ,2 ]
Dvorak, V [1 ,4 ]
Pilka, R. [1 ,3 ]
机构：
[1] HPV Coll Os, Brno, Czech Republic
[2] Gynekol Porodnicka Klin 1 LF UK & VFN, Apolinarska 18, Prague 12853 2, Czech Republic
[3] Porodnicko Gynekol Klin FN & LP UP, Olomouc, Czech Republic
[4] Ctr Ambulantni Gynekol & Primarni Pece, Brno, Czech Republic
来源：
CESKA GYNEKOLOGIE-CZECH GYNAECOLOGY | 2015年 / 80卷 / 06期
关键词：
HPV infection; prevention; nine-valent HPV vaccine;
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Objective: To evaluate current knowledge about new generation of HPV vaccine - nine-valent vaccine Gardasil9. Design: Review article. Results: The nine-valent vaccine against HPV 6/11/16/18/31/33/45/52/58 could improve efficacy of quadrivalent vaccine from 70 to 90 percent for cervical cancer. In addition this vaccine has covered around 85-90% of HPV-related vulvar, vaginal and anal cancers. Efficacy and immunogenicity against HPV 6/11/16/18 is the same as for quadrivalent vaccine. Efficacy against HPV 31/33/45/52/58 associated lesions is 97%.
引用
收藏
页码：397 / 400
页数：4
相关论文
共 50 条
  • [1] From the monovalent to the nine-valent HPV vaccine
    Pils, S.
    Joura, E. A.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (09) : 827 - 833
  • [2] Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
    Gee, Julianne
    Weinbaum, Cindy
    Sukumaran, Lakshmi
    Markowitz, Lauri E.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (06) : 1406 - 1417
  • [3] Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
    Mennini, Francesco Saverio
    Bonanni, Paolo
    Bianic, Florence
    de Waure, Chiara
    Baio, Gianluca
    Plazzotta, Giacomo
    Uhart, Mathieu
    Rinaldi, Alessandro
    Largeron, Nathalie
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [4] Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
    Francesco Saverio Mennini
    Paolo Bonanni
    Florence Bianic
    Chiara de Waure
    Gianluca Baio
    Giacomo Plazzotta
    Mathieu Uhart
    Alessandro Rinaldi
    Nathalie Largeron
    [J]. Cost Effectiveness and Resource Allocation, 15
  • [5] MECHANISMS OF HPV VACCINE KNOWLEDGE LEVELS UNDER RESTRICTED SUPPLY OF NINE-VALENT VACCINE IN CHINA MAINLAND
    Wang, J.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S252 - S252
  • [6] ESTIMATING THE COST-EFFECTIVENESS PROFILE OF A VACCINATION PROGRAMME WITH A NINE-VALENT HPV VACCINE IN ITALY
    Mennini, F. S.
    Bianic, F.
    Baio, G.
    Largeron, N.
    Plazzotta, G.
    Rinaldi, A.
    De Waure, C.
    Bonanni, P.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A457 - A457
  • [7] A qualitative study of healthcare provider awareness and informational needs regarding the nine-valent HPV vaccine
    Kasting, Monica L.
    Wilson, Shannon
    Dixon, Brian E.
    Downs, Stephen M.
    Kulkarni, Amit
    Zimet, Gregory D.
    [J]. VACCINE, 2016, 34 (11) : 1331 - 1334
  • [8] ESTIMATING THE COST-EFFECTIVENESS PROFILE OF A UNIVERSAL VACCINATION PROGRAMME WITH A NINE-VALENT HPV VACCINE IN AUSTRIA
    Boiron, L.
    Joura, E.
    Largeron, N.
    Prager, B.
    Nikoglou, T.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A585 - A585
  • [9] Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
    Boiron, L.
    Joura, E.
    Largeron, N.
    Prager, B.
    Uhart, M.
    [J]. BMC INFECTIOUS DISEASES, 2016, 16
  • [10] Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
    L. Boiron
    E. Joura
    N. Largeron
    B. Prager
    M. Uhart
    [J]. BMC Infectious Diseases, 16
12345